-

06:27:09 PM

CHRS Stock News

CHRS - Coherus Biosciences Inc

03/06/23 4:01 PM

Nasdaq : CHRS

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results

– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 – – FDA is planning the toripalimab manufacturing site inspection in Q2 2023 – – UDENYCA ® autoinjector approved by FDA; UDENYCA ® on-body injector under review by FDA – – Planning underway for potential

RHEA-AI

neutral

03/06/23 8:00 AM

Nasdaq : CHRS

fda approval

FDA Approves UDENYCA® Autoinjector

- UDENYCA ® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy - - An additional presentation, the UDENYCA ® proprietary on-body

RHEA-AI

positive

03/01/23 8:25 AM

Nasdaq : CHRS

conferences

Coherus BioSciences to Present at Upcoming Investor Conferences in March

Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43rd Annual Cowen Health Care Conference on Tuesday, March 7 th at 2:10 p.m. ET Barclays

RHEA-AI

neutral

02/28/23 8:25 AM

Nasdaq : CHRS

conferencesearnings

Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus’

RHEA-AI

neutral

02/15/23 8:25 AM

Nasdaq : CHRS

clinical trial

Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd

RHEA-AI

very positive

02/13/23 8:25 AM

Nasdaq : CHRS

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

RHEA-AI

positive

02/03/23 5:30 PM

Nasdaq : CHRS

Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 1, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 shares

RHEA-AI

very positive

01/09/23 8:20 AM

Nasdaq : CHRS

acquisition

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge

RHEA-AI

very positive

01/04/23 7:01 AM

Nasdaq : CHRS

conferences

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time. The presentation

RHEA-AI

neutral

12/24/22 12:01 AM

Nasdaq : CHRS

Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Coherus and Junshi Biosciences are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next